The nanopore
sequencing market is expected to grow at a CAGR of
approximately 11% during the forecast period, which is primarily
driven by the increasing demand for real-time and field-portable DNA sequencing
technology, especially in infectious disease studies and clinical diagnostics.
However, the market may be hindered due to higher error rates in this sequencing
and lack of standardization protocols for sample preparation.
Nanopore sequencing is a DNA sequencing technique that
interprets genetic material by detecting alterations in electric current when
strands of DNA or RNA pass through a protein pore inserted within a membrane.
In contrast to conventional sequencing platforms, the process does not need
amplification or labeling of nucleic acid. It supports long-read sequencing in
real time and is particularly important for the discovery of structural
variants and complex genomic rearrangements. Its portability and flexibility
have expanded new avenues across areas from environment monitoring to rapid
pathogen identification in remote settings.
To request a free sample copy of this report, please
visit below
https://meditechinsights.com/nanopore-sequencing-market/request-sample/
Real-time diagnostics fuel adoption of portable nanopore
sequencing
The increasing adoption of nanopore sequencing in clinical
diagnostics and infectious disease monitoring is the primary factor driving
market growth. Its capacity to deliver fast, real-time genomic information in
near-patient environments is radically changing the way diseases are identified
and tracked. During outbreaks such as COVID-19 and antimicrobial resistance,
the portability and speed of nanopore devices enabled scientists and health
officials to conduct field-based genetic sequencing, unlike with cumbersome
laboratory-based platforms. This field suitability has not just accelerated the
timeframe to actionable answers but has also democratized access to genomic
information in resource-poor settings. Additionally, clinicians can now track
viral mutations and trends in bacterial resistance more nimbly, and this means
more accurate and timely interventions. With healthcare trending towards
advancements in personalized medicine and rapid diagnostics, the practical
usefulness of nanopore sequencing is becoming increasingly clear, with a firm
foundation in both day-to-day clinical labs and global health initiatives.
Biochemical upgrades drive precision in nanopore
sequencing tools
One of the key innovations that has improved the performance
and reliability of nanopore sequencing is the creation of R10 nanopores. In
contrast to previous generations, R10 nanopores have dual reader heads that
enhance the resolution of DNA strand detection, particularly in challenging
areas such as homopolymers. This has had a direct impact on improved consensus
accuracy, solving one of the most quoted limitations of the technology. In
addition to these advances, improvements in motor proteins that regulate the
rate at which DNA is passed through the pore have notably enhanced signal
stability and readability. These innovations are essential since they enable
researchers to obtain more consistent results without compromising on the
fundamental advantage of portability and the ability to produce long reads. By
focusing on the biochemical mechanics of sequencing rather than
computation-based solutions to these problems, these innovations make the
technology robust, broadening its appeal for research and
diagnostic uses that require greater accuracy.
Competitive Landscape Analysis
The global nanopore sequencing market is marked by the
presence of established and emerging market players such as QIAGEN, Oxford
Nanopore Technologies Limited, Eurofins Scientific, Agilent Technologies, Inc.,
F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Danaher
Corporation, PerkinElmer Inc., Thermo Fisher Scientific, Pacific
Biosciences, and Myriad Genetics, Inc. among others. Some of the
key strategies adopted by market players include new product development,
strategic partnerships and collaborations, and geographic expansion.
🔗 Want deeper insights? Download the
sample report here:
https://meditechinsights.com/nanopore-sequencing-market/request-sample/
Global Nanopore Sequencing Market Segmentation
This report by Medi-Tech Insights provides the size of
the global nanopore sequencing market at the regional- and country-level
from 2023 to 2030. The report further segments the market based on product,
type of nanopore, type of nucleotide sequenced, application and end-user.
Market Size & Forecast (2023-2030), By Product, USD
Million
- Instruments
- Consumables
Market Size & Forecast (2023-2030), By Type of
Nanopore, USD Million
- Solid
State
- Biological
- Hybrid
Market Size & Forecast (2023-2030), By Type of
Nucleotide Sequenced, USD Million
- DNA
- RNA
Market Size & Forecast (2023-2030), By Application,
USD Million
- Human
Genetics
- Clinical
Research
- Animal
Research
- Others
Market Size & Forecast (2023-2030), By End-user, USD
Million
- Biotechnological
Companies
- Clinical
Laboratories
- Academic
& Research Institutes
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment